CATX – perspective therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock.
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
Form 8-K Perspective Therapeutics For: Jan 14
Form 8-K Perspective Therapeutics For: Jan 12
Form 8-K Perspective Therapeutics For: Jan 09
Form SCHEDULE 13G/A Perspective Therapeutics Filed by: FMR LLC
Form 8-K Perspective Therapeutics For: Dec 01
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.